Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response evaluation of AryoSeven in hemophilia patients with inhibitors
IRCT20161202031193N3Phase 2Completed
- Sponsor
- AryoGen Biopharma
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of AryoSeven and coagulation factor VIIa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by AryoGen Biopharma. Primary endpoints: Thrombin generation assay, D-dimer and 2 more. Started Dec 2020; status: completed.
02
Drugs
AryoSevencoagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on IRCT20161202031193N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161202031193N3.